Analysis of revumenib-REVUFORJ market pricing, reference price range and formal drug purchase channels

Revumenib-REVUFORJis a drug targeting KMT2A rearranged acute myeloid leukemia (AML< span>) and acute lymphoblastic leukemia (ALL), new targeted drugs inhibit the function of abnormal fusion proteins, block tumor cell proliferation and induce apoptosis, providing precise treatment options for patients with specific gene mutations. The drug has shown significant efficacy in clinical trials and is especially suitable for patients who have relapsed or been refractory after multiple lines of chemotherapy, becoming a new direction in precision anti-cancer treatment.

In terms of market pricing, Revimenib has not yet been officially launched in China, so patients need to obtain the original drug through overseas channels. The specifications of the US version of the original drug include 110 mg 30 tablets and 160 mg 30 tablets. Each box is priced at about 200,000 yuan, which is very expensive, reflecting its research and development costs, scarcity and high added value of targeted therapy. This puts some patients under great pressure in terms of financial affordability, and also limits the popularity and use of drugs in the country.

In overseas markets, generic drugs of Revemenib have been launched. The ingredients of the drug are basically the same as those of the original drug, but the price is significantly lower than that of the original drug. For example, the price of 110mg30 tablets produced by Lucius in Laos is about 6200 RMB per box, and the price of 160mg30 tablets per box is about 8300RMB. This type of generic drugs provides a viable option for patients with limited economic conditions. However, when purchasing cross-border drugs, patients must ensure that the channels are formal and the sources of drugs are reliable, and they must pay attention to transportation and storage conditions to ensure drug safety and efficacy.

Overall, Revimenib has clear clinical value in the precise treatment of KMT2A-related leukemia patients. However, since it has not yet been launched in the country, drug purchase channels mainly rely on overseas original drugs and generic drugs. Original drugs are expensive, while generic drugs are relatively cheap, but they also need to be purchased legally and compliantly. Patients should fully understand the price, drug purchase channels and financial affordability before use, and at the same time, standardize medication use under the guidance of professional doctors to ensure efficacy and safety.

Reference materials:https://www.drugs.com/clinical_trials/revumenib.html